These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33076989)

  • 21. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis.
    Ishida S; Koto T; Nagai N; Oike Y
    Jpn J Ophthalmol; 2010 Nov; 54(6):594-601. PubMed ID: 21191722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
    PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.
    Paris D; Quadros A; Humphrey J; Patel N; Crescentini R; Crawford F; Mullan M
    Brain Res; 2004 Feb; 999(1):53-61. PubMed ID: 14746921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice.
    Tanaka Y; Matsuwaki T; Yamanouchi K; Nishihara M
    Neuroscience; 2013 Feb; 231():49-60. PubMed ID: 23201826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of nilvadipine on the cardiovascular system in experimental animals.
    Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T
    Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of nilvadipine on the development of neurological deficits in stroke-prone spontaneously hypertensive rats.
    Takakura S; Furuichi Y; Yamamoto T; Ogawa T; Satoh H; Mori J
    Stroke; 1994 Mar; 25(3):677-82; discussion 682-3. PubMed ID: 8128525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The accumulation of brain injury leads to severe neuropathological and neurobehavioral changes after repetitive mild traumatic brain injury.
    Gao H; Han Z; Bai R; Huang S; Ge X; Chen F; Lei P
    Brain Res; 2017 Feb; 1657():1-8. PubMed ID: 27923640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation
    Schweig JE; Yao H; Coppola K; Jin C; Crawford F; Mullan M; Paris D
    J Biol Chem; 2019 Sep; 294(36):13378-13395. PubMed ID: 31324720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOE Genotype Specific Effects on the Early Neurodegenerative Sequelae Following Chronic Repeated Mild Traumatic Brain Injury.
    Muza P; Bachmeier C; Mouzon B; Algamal M; Rafi NG; Lungmus C; Abdullah L; Evans JE; Ferguson S; Mullan M; Crawford F; Ojo JO
    Neuroscience; 2019 Apr; 404():297-313. PubMed ID: 30711612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
    Brogden RN; McTavish D
    Drugs Aging; 1995 Feb; 6(2):150-71. PubMed ID: 7711361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of atherogenesis in cholesterol-fed rabbits treated with nilvadipine, a new vasoselective calcium entry blocker.
    Koibuchi Y; Sakai S; Miura S; Ono T; Shibayama F; Ohtsuka M
    Atherosclerosis; 1989 Oct; 79(2-3):147-55. PubMed ID: 2597224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.
    Tokuma Y; Fujiwara T; Noguchi H
    Res Commun Chem Pathol Pharmacol; 1987 Aug; 57(2):229-37. PubMed ID: 3659571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine.
    Izumi H; Jinno Y; Kaneta S; Tanaka Y; Okada Y; Izawa T; Ogawa N
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):189-97. PubMed ID: 7475042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic gliosis and behavioral deficits in mice following repetitive mild traumatic brain injury.
    Mannix R; Berglass J; Berkner J; Moleus P; Qiu J; Andrews N; Gunner G; Berglass L; Jantzie LL; Robinson S; Meehan WP
    J Neurosurg; 2014 Dec; 121(6):1342-50. PubMed ID: 25267088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isoorientin, a GSK-3β inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice.
    Tan X; Liang Z; Li Y; Zhi Y; Yi L; Bai S; Forest KH; Nichols RA; Dong Y; Li QX
    Behav Brain Res; 2021 Feb; 398():112968. PubMed ID: 33069740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Astaxanthin improves cognitive performance in mice following mild traumatic brain injury.
    Ji X; Peng D; Zhang Y; Zhang J; Wang Y; Gao Y; Lu N; Tang P
    Brain Res; 2017 Mar; 1659():88-95. PubMed ID: 28048972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells.
    Otori Y; Kusaka S; Kawasaki A; Morimura H; Miki A; Tano Y
    Brain Res; 2003 Jan; 961(2):213-9. PubMed ID: 12531488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulforaphane Inhibits the Generation of Amyloid-β Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice.
    Hou TT; Yang HY; Wang W; Wu QQ; Tian YR; Jia JP
    J Alzheimers Dis; 2018; 62(4):1803-1813. PubMed ID: 29614663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer's disease mouse model.
    Khan MZ; Zhuang X; He L
    Neurobiol Learn Mem; 2016 May; 131():46-55. PubMed ID: 26976092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.